Intracardiac QT variability in patients with structural heart disease on class III antiarrhythmic drugs.
We previously showed that increased intracardiac repolarization lability predicts life-threatening ventricular arrhythmias in patients with structural heart disease. Patients with structural heart disease frequently take antiarrhythmic drugs (AADs), which directly affect repolarization. The effect of AADs on the predictive value of repolarization lability is unknown. We hypothesized that increased intracardiac beat-to-beat QT variability predicts sustained ventricular tachyarrhythmias in structural heart disease patients on class III AADs. Intracardiac electrograms and surface electrocardiogram were simultaneously recorded at rest for 5 minutes in 500 patients (mean +/- SD age, 61 +/- 14 years; 368 male [74%]) with implanted implantable cardioverter-defibrillator for primary (295 patients, or 79%) or secondary prevention of sudden cardiac death. Mean (SD) follow-up currently reached 24.8 (11.7) months. Intracardiac QT variability index was an independent predictor of ventricular tachycardia/ventricular fibrillation events and fast ventricular arrhythmias with cycle length of 240 ms or less in the multivariate Cox model. Intracardiac QT variability was higher in patients on class III AADs than in those not taking these drugs. Increased intracardiac QT variability after adjustment for class III AADs use carried independent risk of life-threatening ventricular tachyarrhythmias.
Tereshchenko
Larisa G
LG
The Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD 21287, USA.
Fetics
Barry J
BJ
Berger
Ronald D
RD
D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D004562:Electrocardiography / Q000187:drug effects* / Q000706:statistics & numerical data*; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016019:Survival Analysis; D015996:Survival Rate; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000401:mortality* / Q000517:prevention & control*; D016896:Treatment Outcome; D014481:United States
D000889:Anti-Arrhythmia Agents